Close

AstraZeneca and Cancer Research UK collaborate for new cancer medicines screening

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Ensuring optimal product integrity with pharmaceutical preservation strategies

Preserving the potency of pharmaceutical products is paramount in...

How Stem Cell Therapy Works for the Individual

Stem cell therapy has emerged as one of the...

Tjoapack Expands Injectable Packaging Capabilities Globally

Increased Capabilities in the United States Tjoapack is finishing up...

British-Swedish drugmaker AstraZeneca has signed a memorandum of understanding (MoU) to provide drug discovery facilities for Cancer Research UK at its new MRC UK Centre for Lead Discovery in Cambridge.

As part of the five-year collaboration, researchers from Cancer Research UK will be provided access to two million molecules in AstraZeneca’s compound library.

Access will also be available to screening tools at the facility, located within its new site at the Cambridge Biomedical Campus.

Cancer Research UK translational research funding head Alexa Smith said: “Having access to AstraZeneca’s extensive compound library and innovative drug discovery technology will help our researchers quickly translate new discoveries into patient benefit.”

Advanced screening methods will be used to detect lead compounds within the compound library including fragment-based lead generation, under which small chemical fragments are screened against drug targets.

The collection of compounds being screened are useful for blocking kinase drug targets and phenotypic screens to identify active compounds within cells that could be the starting point for new drugs.

Screening scientists from both organisations will work alongside each other on up to five drug screens annually.

Cancer Research UK will select novel cancer drug discovery projects to investigate, while AstraZeneca will have the option to negotiate a commercial license with Cancer Research Technology, Cancer Research UK’s commercial arm, to progress promising candidates through further drug discovery and development.

Latest stories

Related stories

Ensuring optimal product integrity with pharmaceutical preservation strategies

Preserving the potency of pharmaceutical products is paramount in...

How Stem Cell Therapy Works for the Individual

Stem cell therapy has emerged as one of the...

Tjoapack Expands Injectable Packaging Capabilities Globally

Increased Capabilities in the United States Tjoapack is finishing up...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back